This content is not available in your region

Novartis boosts 2019 outlook on rising Cosentyx, Entresto sales

Novartis boosts 2019 outlook on rising Cosentyx, Entresto sales
FILE PHOTO: Switzerland's national flag flies in front of the logo of Swiss drugmaker Novartis in Basel, Switzerland, January 30, 2019. REUTERS/Arnd Wiegmann/File Photo   -   Copyright  Arnd Wiegmann(Reuters)
Text size Aa Aa

ZURICH (Reuters) – Swiss drugmaker Novartis on Wednesday raised its 2019 guidance after a first-quarter earnings and sales beat, as revenue from its heart failure drug Entresto and psoriasis medicine Cosentyx continued to grow.

First-quarter core net income rose 13 percent at constant exchange rates to $2.81 billion (£2.17 billion), compared to the $2.76 billion average estimate in a poll by Infront Data. Sales excluding Alcon, spun off to shareholders this month, rose 7 percent to $11.1 billion, compared to the $10.9 billion poll average.

Novartis now expects core operating income growth at a high-single-digit percentage rate, with sales growing in the mid-single-digit percentage range. It had seen net sales growing by a low- to mid-single-digit percentage, with core operating income up at a mid-single-digit rate.

(Reporting by John Miller; Editing by Michael Shields)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.